1. It is important to understand the safety profile of selective serotonin reuptake inhibitors with regard to teratogenicity.
INTRODUCTION
Recent evidence suggests that approximately 10% to 15% of women will experience major depressive disorder in the perinatal period, which is at least as common as rates reported for women in nonreproductive states. (1)(2) Use of antidepressant medications, particularly selective serotonin reuptake inhibitors (SSRIs), also called serotonin reuptake inhibitors, has increased significantly among pregnant women in recent decades. (3) These agents, which traverse the placenta, have been inconsistently implicated in congenital anomalies in children whose mothers were exposed to SSRIs during the first trimester. In addition, SSRI use during and throughout pregnancy may have additional implications for neonatal outcomes. This review aims to explore the current evidence for SSRI use in pregnancy with a focus on teratogenicity, neonatal adaptation syndrome, persistent pulmonary hypertension of the newborn (PPHN), and breastfeeding.
CONGENITAL ANOMALIES AND SSRIs
A considerable amount of literature has been published on SSRIs and birth defects with conflicting findings. The results of these studies can best be categorized under 2 headings: studies that demonstrate teratogenicity related to SSRI exposure or potential exposure (Table 1) , and studies that demonstrate no evidence of teratogenicity related to SSRI exposure or potential exposure (Table 2) .
STUDIES DEMONSTRATING TERATOGENIC EFFECT
Studies demonstrating teratogenicity are primarily retrospective and case control in nature, with their inherent limitations. A register-based retrospective cohort study from Denmark (N¼1,051) found that for any SSRI prescription filled from 30 days before conception until the end of the first trimester, there was a higher risk for cardiovascular malformations (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.1-1.8). (4) Another study in 2012 from the same database found that offspring of women filling a prescription for an SSRI during the first trimester of pregnancy (N¼4,183) had an increase in major anomalies (OR, 1.33; 95% CI, 1.16-1.53) and congenital heart defects (OR, 2.01; 95% CI, 1.60-2.53). (5) They also found an association between exposure to SSRIs in the first trimester and craniosynostosis, with an adjusted OR of 1.94 (95% CI, 1.00-3.76). A cohort study based on Danish administrative register data linked with the Danish EUROCAT that included 72,290 patients demonstrated an increased risk for severe congenital heart disease in children of women who used SSRIs in the first trimester (adjusted OR [aOR], 4.03; 95% CI, 1.75-9.26). (6) A Nordic register-based case-control study included a sibling controlled design with 36,772 liveborn infants with presumed first-trimester exposure to any SSRI. (7) Risk estimates were increased for all major malformations combined (aOR, 1.13; 95% CI, 1.06-1.20), any cardiac defect (aOR, 1.15; 95% CI, 1.05-1.26), clubfoot (aOR, 1.34; 95% CI, 1.05-1.71), and omphalocele (aOR, 2.11; 95% CI, 1.01-4.39). However, the sibling controlled analysis that only included sibling pairs discordant for the exposure to SSRIs showed no increased risk for any of the aforementioned malformations; this suggests that the small increased risk found initially could be explained by unadjusted factors. (7) The EUROCAT database compared SSRI exposure among cases with congenital heart defects or other malformations and controls. (8) The study failed to confirm prior associations with anencephaly, craniosynostosis, or limb reduction defects for presumed exposure to any SSRI. The study confirmed previously reported increased risk estimates for clubfoot (aOR, 2.41; 95% CI, 1.59-3.65) and renal dysplasia (aOR, 3.01; 95% CI, 1.61-5.61). The study also found heightened risk estimates for congenital heart defects combined (aOR, 1.41; 95% CI, 1.07-1.86), as well as increased risks specifically for tetralogy of Fallot (aOR, 3.16; 95% CI, 1.52-6.58) and Ebstein anomaly (aOR, 8.23; 95% CI, 2.92-23.16), neither of which had been previously reported in association with SSRIs. In addition, the risk estimates were increased for anorectal atresia and stenosis (aOR, 2.46; 95% CI, 1.06-5.68) and gastroschisis (aOR, The inconsistency across these studies may potentially be explained by differences in study design, or by confounding factors, such as maternal obesity, diabetes, or coadministered medications.
STUDIES THAT DEMONSTRATE NO TERATOGENICITY WITH SSRI USE
The balance of prospective studies and meta-analyses suggest no increased risk of teratogenicity and SSRI use. In a prospective, controlled, multicenter cohort study, mothers who contacted a teratology information service regarding the use of SSRIs were followed through their pregnancies (N¼267). (15) The incidence of malformations in children born to women taking SSRIs was 4.1%, comparable to that found in the unexposed control subjects at 3.8%. Furthermore, a recent register-based prospective study from Sweden that included 17,736 infants exposed to SSRIs in utero found the same risk of total malformations (2.2%), cardiac defects (0.8%), and infant mortality within 28 days of birth (0.1%) compared to no SSRI exposure. (23) A nested cohort study using US Medicaid claims data (N¼949,504) was consistent with the previously mentioned studies, with no increase in any cardiac malformation associated with prescription of an SSRI during the first trimester of pregnancy after adjustment for maternal illness (0.9% exposed vs 0.7% nonexposed; adjusted RR, 1.06; 95% CI, 0.93-1.22). (27) A 2006 meta-analysis on SSRIs and pregnancy reported no difference for major malformations (OR, 1.39; 95% CI, 0.91-2.15) and cardiovascular malformations (OR, 1.19; 95% CI, 0.53-2.68). (28) A meta-analysis of 4 prospective cohort studies published in 2015 reported that there was no increased risk for presumed exposure to SSRIs and congenital cardiac defects combined, with a pooled adjusted OR of 1.06 (95% CI, 0.94-1.18). (29) 
NEONATAL ADAPTATION
Poor neonatal adjustment syndrome, neonatal behavioral syndrome, or neonatal abstinence syndrome are used interchangeably to describe a constellation of signs and symptoms that occur after in utero exposure to SSRI; toxicity and withdrawal are both potential explanations for this syndrome. (30) Multiple scoring systems have been developed to evaluate the severity of neonatal withdrawal to opiates and other substances (31)(32)(33); these scoring systems have been successfully translated to SSRI exposure. The Finnegan scoring system is one of the most widely used and comprises signs and symptoms that reflect different disturbances within the central nervous system, as well as the vasomotor, gastrointestinal, metabolic, and respiratory systems. Large cohort studies have consistently demonstrated an increased risk of developing neonatal abstinence syndrome with third-trimester use of SSRIs.
One study examined poor neonatal adaptation in 247 infants exposed to SSRIs in the third trimester who were admitted for observation after delivery. (34) Poor neonatal adaptation was defined as having a Finnegan score of at least 4 on 1 occasion during the 72-hour observation period. There were 187 infants with exposure to an SSRI; for all SSRIs combined, 127 infants had poor neonatal adaptation, but only 5 required a NICU admission. Formula feeding was associated with an increased risk of poor neonatal adaptation compared with breastfeeding or mixed feeding (OR, 3.16; 95% CI, 1.40-7.13; P¼.003).
Another study associated SSRI exposure during pregnancy with poorer self-regulation and higher levels of arousal in infants during the first month after birth. (35) No association was found with admission to a NICU. Overall, as studies demonstrate a heightened risk for neonatal adaptation syndrome, neonates exposed prenatally to SSRIs should be evaluated for signs of adverse effects. However, the incidence and severity of these effects do not appear to be so frequent or severe that women should avoid using these medications if they are otherwise indicated. (40) PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN PPHN is a syndrome characterized by the presence of high pulmonary vascular resistance and right-to-left shunting. Contrary to the primary pulmonary arterial hypertension of the adult, the syndrome of the newborn is not defined by a specific pressure of the pulmonary circulation. Hypoxia with right-to-left shunt and absence of congenital anomalies of the heart confirms the diagnosis. An increase in PPHN associated with late (41) The FDA stated that the initial public health advisory in July 2006 about this potential risk was based on a single published study. Since then, conflicting findings have been seen in newer studies evaluating this potential risk, making it unclear whether the use of SSRIs during pregnancy can cause PPHN. The FDA concluded that given the conflicting results from different studies, it was premature to reach any conclusion about a possible link between SSRI use in pregnancy and PPHN. After the publication of the FDA statement, a multinational record-linkage study reported an increase in PPHN in offspring born to women who had filled a prescription for an SSRI late in pregnancy, with an aOR of 2.1 (95% CI, 1.5-3.0). (48) Since then, a meta-analysis of 7 studies published through 2012 concluded that third-trimester exposure to SSRIs as a group was associated with PPHN (OR, 2.50; 95% CI, 1.32-4.73; P¼.005), while first-trimester exposure was not (OR, 1.23; 95% CI, 0.58-2.60; P¼.58). (49) Norby et al found that the rate of PPHN was increased in preterm and term infants exposed during pregnancy to SSRIs. (23) For term infants only, the rate of PPHN was higher with exposure in the third trimester compared with exposure in the first or second trimester only, with the number needed to harm of 285. It appears that there is an association between third-trimester SSRI use and PPHN, but the association is weak (OR, 2.50). Clinicians should weigh the risks and benefits of SSRIs and this weak association with PPHN against the primary obligation to maintain maternal mood stability.
BREASTFEEDING
All SSRIs cross the blood-milk barrier and are excreted in breast milk, with an estimated relative infant dose less than 2% of weight-adjusted maternal dose. (50) SSRIs have different safety profiles with breastfeeding (Table 3) . Fluoxetine and citalopram are excreted in larger amounts, reaching infant plasma levels that can exceed 10% of the maternal concentration. (51)(52) Conversely, the relative infant doses are low for fluvoxamine, paroxetine, and sertraline. (51) Adverse events in breastfed infants exposed to SSRIs through breast milk have been suspected in a few cases, more often with fluoxetine and citalopram. (52) For example, crying, irritability, decreased feeding, and diarrhea have been reported for fluoxetine, (38)(52)(53)(54)(55) while hypotonia, colic, decreased feeding, and sleep difficulties have been described for citalopram. (52)(56)(57) Some studies suggest avoidance of these drugs in the medication-naïve postpartum patient. (38)(50)(57) However, if the neonate was exposed to these antidepressants in utero, the impact of postnatal exposure through milk is much lower and breastfeeding is recommended. (38)(50) (52) Furthermore, breastfeeding has consistently been shown to mitigate neonatal adaptation symptoms faster than formula feeding in infants exposed to SSRIs during the third trimester of pregnancy. The well-documented advantages of breastfeeding (eg, nutritional, immunologic) appear to outweigh the potential risks of SSRI use during breastfeeding. (58) Given this, both the American Academy of Pediatrics (49) and the National Institutes of Health (46) consider SSRIs compatible with breastfeeding.
CONCLUSION
The choice to initiate SSRI treatment during pregnancy must be individualized for each patient, and include a discussion with her clinician, weighing the risks, benefits, and alternatives. With regard to teratogenicity, studies vary in quality and design, but large prospective studies suggest an overall minimal increased risk to first-trimester exposure to an SSRI. From a neonatal standpoint, familiarity with potential conditions associated with antenatal exposure to SSRIs, including poor neonatal adaptation and PPHN, can guide patient counseling if medication is initiated, and improve postnatal detection and management. Given that untreated maternal depression is associated with poor
